NCT02027103View on ClinicalTrials.gov

Metformin and Pioglitazone Effects on Fetuin-A and Osteoprotegrin Concentrations in Type 2 Diabetes Patients

NACompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

March 31, 2012

Study Completion Date

April 30, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Metformin

Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)

DRUG

Pioglitazone

Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)

Trial Locations (1)

13145-784

Diabetes Clinic, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran

All Listed Sponsors
lead

Tehran University of Medical Sciences

OTHER

NCT02027103 - Metformin and Pioglitazone Effects on Fetuin-A and Osteoprotegrin Concentrations in Type 2 Diabetes Patients | Biotech Hunter | Biotech Hunter